5 Best Immunotherapy Stocks To Buy Now

Page 5 of 5

1. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders: 35   

argenx SE (NASDAQ:ARGX) is a biotechnology company that focuses on developing various therapies for the treatment of autoimmune diseases. It is one of the elite immunotherapy stocks to invest in. Argenx SE (NASDAQ:ARGX) recently submitted an application to the US Food and Drug Administration (FDA) seeking approval of subcutaneous (SC) efgartigimod to treat adult patients with generalized myasthenia gravis (gMG).The Biologics License Application was backed by data from a phase 3 trial called ADAPT-SC, which showed non-inferiority of SC efgartigimod compared to intravenously administered Vyvgart.

On August 26, Piper Sandler analyst Allison Bratzel kept an Overweight rating on Argenx SE (NASDAQ:ARGX) stock and raised the price target to $465 from $450, stating that the feedback indicates strong initial demand among refractory patients driving early uptake, which bodes well for Vyvgart, a pipeline drug of the firm. 

At the end of the second quarter of 2022, 35 hedge funds in the database of Insider Monkey held stakes worth $2.4 billion in argenx SE (NASDAQ:ARGX), compared to 31 in the preceding quarter worth $1.95 billion. 

In its Q2 2022 investor letter, Artisan Partners, an asset management firm, highlighted a few stocks and argenx SE (NASDAQ:ARGX) was one of them. Here is what the fund said:

“argenx SE (NASDAQ:ARGX) is a commercial stage biotechnology company with an approved, first-, and potentially best-in-class therapy (FcRn) for autoimmune diseases. In its first full quarter of sales, Vyvgart meaningfully exceeded consensus sales expectations, indicating strong early market traction. In addition, it released positive phase 3 results for Vyvgart’s use in treating immune thrombocytopenia purpura, a blood disorder characterized by low platelet levels. We believe this second indication could receive FDA approval in early 2023, and the news confirms our thesis that Vyvgart is a “pipeline in a product”—a compelling new molecule which is likely to be safe and effective in numerous rare autoimmune disorders.”

You can also take a peek at 10 Best Stocks to Buy According to Angela Aldrich’s Bayberry Capital Partners and Top 10 Tech Stocks to Buy According to Billionaire Louis Bacon.

Page 5 of 5